Position statement on the use of biosimilars in inflammatory bowel disease | Zendy

Emanuel Burri | Zendy; Pascal Juillerat | Zendy; Michel H. Maillard | Zendy; Markus G. Manz | Zendy; Pierre Michetti | Zendy; Christian Mottet | Zendy; Gerhard Rogler | Zendy; Nadine Zahnd | Zendy; Stephan R. Vavricka | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Position statement on the use of biosimilars in inflammatory bowel disease

Author(s) -

Emanuel Burri,

Pascal Juillerat,

Michel H. Maillard,

Markus G. Manz,

Pierre Michetti,

Christian Mottet,

Gerhard Rogler,

Nadine Zahnd,

Stephan R. Vavricka

Publication year - 2019

Publication title -

schweizerische medizinische wochenschrift

Language(s) - English

Resource type - Journals

ISSN - 0036-7672

DOI - 10.4414/smw.2019.20148

Subject(s) - biosimilar , medicine , position statement , inflammatory bowel disease , intensive care medicine , inflammatory bowel diseases , disease , position paper , risk analysis (engineering) , pharmacovigilance , pharmacology , adverse effect , family medicine , pathology

Biologics are effective and have a good safety profile in the treatment of inflammatory bowel disease. Biosimilars have recently become available as treatment option. They are biological agents that are highly similar to the original biologic compound in their structure, biological activity, efficacy and safety. This position paper summarises current knowledge on biosimilars and presents its statements on regulatory issues and clinical situation in order to provide clinicians adequate information for them to reach informed and appropriate shared decision-making with their patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research